

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

Equality and health inequality impact assessment

**Trastuzumab deruxtecan for neoadjuvant
treatment of HER2-positive early breast
cancer**

Scoping

- 1 Have any potential equality issues been identified during the scoping process? If so, what are they?**

No potential equality issues were identified during the scoping process.

- 2 Have any potential health inequality issues been identified during the scoping process? If so, what are they?**

No potential health inequality issues were identified during the scoping process.

- 3 What is the preliminary view as to what extent the committee needs to address the potential issues set out in questions 1 and 2?**

N/A

- 4 Has any change to the draft scope been agreed to highlight the potential equality or health inequality issues set out in questions 1 and 2 following the scope consultation?**

No

5 Has the stakeholder list been updated as a result of additional equality or health inequality issues identified during the scoping process?

No

Approved by senior responsible officer: Ian Watson

Date: 18/06/2026